AASK: The Cohort Study

高血压性肾病通常会进展。AASK的主要目标(非裔美国人研究 肾脏疾病和高血压)队列研究是前瞻性地确定肾功能和危险因素的病程 高血压肾病患者中非裔美国人肾脏疾病进展的因素 推荐的抗高血压治疗。第二个目标是确定心血管疾病的发生 并评估其风险因素。 AASK队列研究是一项前瞻性观察性研究，是AASK试验的延伸。AASK试验 测试了3种初始降压药物(雷米普利、美托洛尔和氨氯地平)和2种药物的疗效 血压控制水平。该中心的AASK参与者中，约有48人尚未结束- 阶段性疾病将被纳入队列研究。要研究的风险因素包括环境、遗传、 生理和社会经济变量。原发肾脏结局是由以下因素定义的综合临床结局 血肌酐增加一倍，终末期肾病，或死亡。高血压的药物治疗，从血管紧张素开始 转换酶抑制剂雷米普利提供给所有参与者。通过这种方式，研究直接控制了两个 肾脏疾病进展的主要决定因素(高血压的治疗和肾脏保护性药物的使用 抗高血压药物)。队列研究的最短随访期为5年(总计9至12年， 包括AASK审判期间)。 最终，来自AASK队列研究的数据应该会增强我们对以下风险因素和过程的理解 确定肾脏疾病的进展情况。这样的结果可能最终会导致新的战略，推迟或防止 ESRD。

Hypertensive kidney disease commonly progresses. The primary objective of the AASK (African American Study of Kidney Disease and Hypertension) Cohort Study is to determine prospectively the course of kidney function and risk factors for kidney disease progression in African-Americans with hypertensive kidney disease who receive recommended antihypertensive therapy. A secondary objective is to determine the occurrence of cardiovascular disease and assess its risk factors. The AASK Cohort Study is a prospective, observational study that is an extension of the AASK trial. The AASK trial tested the effects of 3 medications used as initial antihypertensive therapy (ramipril, metoprolol and amlodipine) and 2 levels of blood pressure control. Approximately 48 of this Center's AASK participants who have not yet reached end- stage disease will be enrolled into the Cohort Study. Risk factors to be studied include environmental, genetic, physiologic, and socio-economic variables. The primary renal outcome is a composite clinical outcome defined by doubling of serum creatinine, ESRD, or death. Medication treatment for hypertension, beginning with the angiotensin converting enzyme inhibitor ramipril, is offered to all participants. In this fashion, the study directly controls two of the major determinants of kidney disease progression (treatment of hypertension and use of reno-protective, antihypertensive medication). The minimum duration of follow-up in the Cohort Study is 5 years (total of 9 to 12 years, including the period of the AASK trial). Ultimately, data from the AASK Cohort Study should enhance our understanding of the risk factors and processes that determine the progression of kidney disease. Such results might eventually lead to new strategies that delay or prevent ESRD.